Epidemiology and natural history of non-alcoholic fatty liver disease.
about
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVPediatric Non-Alcoholic Fatty Liver DiseaseAssessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Treatment options for nonalcoholic steatohepatitis - a safety evaluation.Non-alcoholic fatty liver and advanced fibrosis in the elderly: Results from a community-based Polish survey.Activin A and follistatin in patients with nonalcoholic fatty liver disease.Emerging and future therapies for nonalcoholic steatohepatitis in adults.Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.Lipid droplets and liver disease: from basic biology to clinical implications.The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults.Fatty liver without a large "belly": Magnified review of non-alcoholic fatty liver disease in non-obese patients.Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease.Chronic consumption of fructose in combination with trans fatty acids but not with saturated fatty acids induces nonalcoholic steatohepatitis with fibrosis in rats.The effect of β-caryophyllene on nonalcoholic steatohepatitis.Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.Non-alcoholic Fatty Liver Disease: A Clinical Update.Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate.Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population.Progress and prospects of circular RNAs in Hepatocellular carcinoma: Novel insights into their function.Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study.A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD.Protective Effect of Meretrix meretrix Oligopeptides on High-Fat-Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis.Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD).Recent advances in understanding and managing non-alcoholic fatty liver disease.Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease.Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular MortalityPNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver diseaseChanges in peroxisome proliferator-activated receptor alpha target gene expression in peripheral blood mononuclear cells associated with non-alcoholic fatty liver disease
P2860
Q28079826-613F636F-A6C8-4260-B759-81EA2ACAE7F0Q33831717-4CF555FF-0536-452E-BB69-4AE89F7D5D6AQ37236384-BB8278CB-D249-4152-8782-7DC77E6446C2Q38641190-BCB86B94-F846-4D86-8E54-53C679FDAA2EQ38713765-F4F146DC-2300-4661-8364-08367250E779Q38794378-2C1062D0-0E08-475E-B17C-0A37B7AE625AQ38821923-0E2D4739-F7E8-46E2-A08E-54289C4953B1Q38827586-FF77FE76-CE56-44AD-8612-E50B8757E4C8Q39183375-A7093B56-1FDA-49F5-AF8D-1EC2D6ED301BQ39253589-C968EFC0-5C7C-4A44-9DB4-AE9B9453C6A7Q39471203-677C8A6C-5534-4E2D-9004-5766B16E348CQ41209147-5FFCBB83-F1B0-4FA5-8125-8A4C380022B3Q41449920-937EEC38-2167-43B5-9B6F-E2D2E2DC33A1Q41583750-25E4502D-539C-4306-B2A7-416CC5F73E10Q42015805-718FC89F-D1A9-4C63-A056-1710EE67B2A3Q45790201-FA5203FC-A3B2-4055-962D-B80C7C4D488FQ45942296-0AB6D11E-CB1D-417B-B56E-0D1EA0822220Q47100244-3AD83128-2F34-469A-85E3-CD445A409F42Q47104903-0A498667-B15F-49DD-B02F-049B436C5E62Q47564331-2BF16EC0-2CDB-4D76-8030-D2CFE982AFF0Q47570425-4DC119EB-585D-4043-BB48-AE554B2BA842Q47746064-723AB3AE-85E3-4FD7-9064-0825AC91376FQ47966842-95A1FBFF-8513-401F-B9D2-6E7A165CF4B4Q48184818-70AB9B50-3E93-4752-82FF-CD663005091CQ50134501-C221D241-80F5-49CB-AAF6-40526FF6D22BQ55266683-6CC8096E-8CD2-4D72-88A8-70BC5211FF9BQ55359842-8C28EDB5-A9C6-4C6A-A444-7E8FB9853209Q55379918-AB73A2D9-AF1B-4FB4-A188-CBCB18F92ADEQ55450597-BABB3D58-9559-4B98-8FD3-06315643F136Q57070326-DBD12AD2-9CD5-487B-9059-2EE5A80DADA4Q58773505-3E9F89DD-0596-4418-97E5-C84FF3A36D99Q59135837-8E229DFE-E717-47E6-82E9-03AE6813C327
P2860
Epidemiology and natural history of non-alcoholic fatty liver disease.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Epidemiology and natural history of non-alcoholic fatty liver disease.
@ast
Epidemiology and natural history of non-alcoholic fatty liver disease.
@en
type
label
Epidemiology and natural history of non-alcoholic fatty liver disease.
@ast
Epidemiology and natural history of non-alcoholic fatty liver disease.
@en
prefLabel
Epidemiology and natural history of non-alcoholic fatty liver disease.
@ast
Epidemiology and natural history of non-alcoholic fatty liver disease.
@en
P2093
P1433
P1476
Epidemiology and natural history of non-alcoholic fatty liver disease
@en
P2093
Mehmet Sayiner
Yousef Fazel
Zachary D Goodman
Zobair M Younossi
P304
P356
10.1016/J.METABOL.2016.01.012
P577
2016-01-29T00:00:00Z